Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STI571 Extension Study in Interferon-Refractory/Intolerant CML
NCT00171223Phase 2Completed
- Sponsor
- Novartis
- Start
- Dec 1999
- Primary completion
- Nov 2013
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, open-label, single-arm trial of imatinib in chronic myeloid leukemia (CML), sponsored by Novartis. Primary endpoint: Percentage of Participants With Cytogenetic Response (Complete Cytogenetic Response and Major Cytogenetic Response) up to 6 years. Started Dec 1999; status: completed.
02
Drugs
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT00171223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00171223.